Teachers Advisors LLC boosted its holdings in Neos Therapeutics, Inc. (NASDAQ:NEOS) by 31.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 38,853 shares of the company’s stock after buying an additional 9,190 shares during the quarter. Teachers Advisors LLC owned approximately 0.17% of Neos Therapeutics worth $284,000 at the end of the most recent quarter.
A number of other large investors have also bought and sold shares of NEOS. State of Wisconsin Investment Board purchased a new position in Neos Therapeutics in the second quarter valued at $102,000. OMERS ADMINISTRATION Corp purchased a new position in Neos Therapeutics in the second quarter valued at $110,000. Rhumbline Advisers increased its holdings in Neos Therapeutics by 13.6% in the second quarter. Rhumbline Advisers now owns 20,409 shares of the company’s stock valued at $149,000 after buying an additional 2,441 shares during the last quarter. Alliancebernstein L.P. purchased a new position in Neos Therapeutics in the second quarter valued at $161,000. Finally, Schwab Charles Investment Management Inc. increased its holdings in Neos Therapeutics by 103.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 43,700 shares of the company’s stock valued at $320,000 after buying an additional 22,200 shares during the last quarter. 44.66% of the stock is currently owned by hedge funds and other institutional investors.
Neos Therapeutics, Inc. (NEOS) opened at $10.15 on Friday. Neos Therapeutics, Inc. has a twelve month low of $4.85 and a twelve month high of $13.15. The company has a current ratio of 2.42, a quick ratio of 2.84 and a debt-to-equity ratio of 4.01.
COPYRIGHT VIOLATION NOTICE: This report was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://sportsperspectives.com/2017/11/19/neos-therapeutics-inc-neos-position-boosted-by-teachers-advisors-llc.html.
Several equities analysts recently commented on NEOS shares. Zacks Investment Research lowered Neos Therapeutics from a “buy” rating to a “sell” rating in a report on Thursday, October 19th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $20.00 price objective on shares of Neos Therapeutics in a report on Tuesday, September 26th. Cowen and Company reaffirmed a “buy” rating on shares of Neos Therapeutics in a report on Thursday, October 26th. Wells Fargo & Company set a $14.00 price objective on Neos Therapeutics and gave the stock a “buy” rating in a report on Wednesday, October 18th. Finally, ValuEngine raised Neos Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 12th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. Neos Therapeutics has an average rating of “Buy” and a consensus price target of $14.00.
Neos Therapeutics Profile
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Want to see what other hedge funds are holding NEOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neos Therapeutics, Inc. (NASDAQ:NEOS).
Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.